Curis, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2000-01-01
- Employees
- 49
- Market Cap
- $35.9M
- Website
- http://www.curis.com
Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies
- First Posted Date
- 2020-07-17
- Last Posted Date
- 2023-10-27
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT04475523
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Conditions
- Myelodysplastic SyndromeAcute Myelogenous Leukemia
- Interventions
- First Posted Date
- 2020-02-20
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 366
- Registration Number
- NCT04278768
- Locations
- 🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸University of Chicago Medical Center, Chicago, Illinois, United States
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- Conditions
- Relapsed Primary Central Nervous System LymphomaRelapsed Hematologic MalignancyRefractory Primary Central Nervous System LymphomaRefractory Hematologic Malignancy
- Interventions
- First Posted Date
- 2017-11-01
- Last Posted Date
- 2025-01-24
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 152
- Registration Number
- NCT03328078
- Locations
- 🇺🇸
St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸City of Hope, Duarte, California, United States
A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas
- First Posted Date
- 2016-06-24
- Last Posted Date
- 2020-06-26
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 71
- Registration Number
- NCT02812875
- Locations
- 🇬🇧
Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom
🇰🇷Yonsei University Health System - Severance Hospital, Seoul, Korea, Republic of
🇺🇸Carolina BioOncology Institute, Huntersville, North Carolina, United States
Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients With RR DLBCL, Including Patients With MYC Alterations
- Conditions
- Relapsed and/or Refractory Diffuse Large B-cell Lymphoma Including With Myc Alterations
- Interventions
- First Posted Date
- 2016-02-04
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 70
- Registration Number
- NCT02674750
- Locations
- 🇺🇸
Charles A. Sammons Cancer Center, Dallas, Texas, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors
- Conditions
- Triple-Negative Breast CancerHigh-grade Serous Ovarian CancerSolid TumorsNUT Midline Carcinoma
- Interventions
- First Posted Date
- 2014-12-04
- Last Posted Date
- 2019-09-03
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02307240
- Locations
- 🇺🇸
UCSF School of Medicine, San Francisco, California, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-427 When Given to Patients With Advanced and Refractory Solid Tumors or Lymphoma
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2016-12-01
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT01908413
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Southern Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma
- Conditions
- LymphomaRelapsed LymphomaRefractory LymphomaRelapsed and/or Refractory LymphomaRelapsed Ddiffuse Large B-Cell Lymphoma (DLBCL)Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Double-expressor Lymphoma (DEL)High-grade B-cell Lymphoma (HGBL)Double-hit Lymphoma (DHL)
- Interventions
- First Posted Date
- 2012-12-06
- Last Posted Date
- 2021-05-06
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 106
- Registration Number
- NCT01742988
- Locations
- 🇺🇸
Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸University of Chicago Medicine, Chicago, Illinois, United States
Phase I Study to Assess the Safety, Tolerability, and Pharmacokinetics of Orally Administered CUDC-101 in Cancer Patients
- First Posted Date
- 2012-10-08
- Last Posted Date
- 2018-02-12
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 3
- Registration Number
- NCT01702285
- Locations
- 🇺🇸
Southern Texas Accelerated Research Therapeutics, San Antonio, Texas, United States
🇺🇸Karmanos Cancer Institute, Detroit, Michigan, United States
Phase I Study of CUDC-101 With Cisplatin and Radiation in Subjects With Head & Neck Cancer
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2011-06-29
- Last Posted Date
- 2018-02-22
- Lead Sponsor
- Curis, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT01384799
- Locations
- 🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States